Robert Wollin Acquires Shares in MeiraGTx Holdings
Robert Wollin, General Counsel at MeiraGTx, purchased 100,000 shares.
Key Points
- Robert Wollin, General Counsel at MeiraGTx, bought 100,000 shares on June 25, 2026, as part of insider activity.
- MeiraGTx Holdings, a biotech company, has a market cap of $1.12 billion and recently traded at $12.54.
- Analysts maintain a strong buy consensus for MGTX, with a mean price target of $28.25.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robert Wollin, the General Counsel and Secretary for MeiraGTx Holdings plc, recently acquired 100,000 shares of the company. This transaction took place on June 25, 2026, and highlights insider activity within the biotech firm. The shares were acquired at no cost, as part of a transaction code marked 'A'.
Insider Buying and Selling at MeiraGTx Holdings plc
In addition to Robert Wollin, several other insiders at MeiraGTx made significant stock purchases on June 25, 2026. President and CEO Alexandria Forbes acquired 980,000 shares, while Chief Scientific Officer Stuart Naylor purchased 70,000 shares. Chief Medical Officer Robert Zeldin and CFO & COO Richard Giroux both added 100,000 and 980,000 shares respectively to their holdings. These transactions were not made under any prearranged trading plan.
Other Institutional Activity in MeiraGTx Holdings
Institutional investors have also been active in MeiraGTx Holdings. Rubric Capital Management LP increased its stake by 824,669 shares, resulting in a 13.4% boost to 7 million shares valued at approximately $60.6 million. Millennium Management LLC added 289,309 shares, a 9.1% increase, bringing its total to nearly 3.47 million shares worth about $30 million. Other major holders like Sanofi and Johnson & Johnson maintained their positions without any change.
MeiraGTx Holdings plc Stock Down 9.3%
As of Tuesday, shares of MeiraGTx Holdings plc (NasdaqGS: MGTX) were trading near $12.54. The biotechnology company has a market capitalization of approximately $1.12 billion. While the firm is not currently profitable, it has a forward P/E ratio of -8.7 and a beta of 1.257, indicating some volatility compared to the broader market. The stock's 52-week range spans from $6.31 to $12.28, with a 50-day moving average of $9.86 and a 200-day average of $8.52.
$MGTX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
MeiraGTx Holdings reported revenue of $79.76 million, though it faced a revenue decline of 84.8%. The company is not currently profitable, with a net margin of -151.1%. MeiraGTx is expected to announce its next earnings on August 13, 2026.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on MeiraGTx Holdings. RBC Capital reiterated its buy rating on May 15, 2026, with a price target of $25. Piper Sandler and Evercore ISI Group also maintained buy ratings with targets of $30 and $18, respectively. Overall, the consensus among analysts is a strong buy, with a mean price target of $28.25 based on eight opinions.
About MeiraGTx Holdings
MeiraGTx Holdings plc is a clinical-stage genetic medicines company based in New York, NY. It focuses on developing treatments for serious diseases, particularly in the areas of ocular and neurodegenerative diseases. The company is involved in several clinical trials for gene therapies targeting conditions like Parkinson's disease and retinal dystrophies. Dr. Alexandria Forbes, Ph.D., serves as the CEO, leading a team of over 400 employees.
Bottom Line
The recent insider buying activity at MeiraGTx Holdings highlights confidence within the company's leadership. This, combined with institutional interest and a positive analyst outlook, makes the stock one to watch. However, it's important to note that 13F filings and insider transactions are backward-looking and may not reflect current positions or future performance.
Get MeiraGTx Holdings plc alerts
New 13F filings, insider trades, and analyst moves on $MGTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.